Human coronaviruses: Insights into environmental resistance and its influence on the development of new antiseptic strategies

Viruses

Volumn 4, Issue 11, 2012, Pages 3044-3068

  Geller, Chloé ^a   Varbanov, Mihayl ^a   Duval, Raphaël E ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Antiseptics disinfectants; Environmental survival; Human coronaviruses

Indexed keywords

DISINFECTANT AGENT; DNA VACCINE; GLYCYRRHIZIC ACID; HYDROCORTISONE; INTERFERON; MONOCLONAL ANTIBODY; NELFINAVIR; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SMALL INTERFERING RNA;

ADENOVIRUS 5; ANTISEPSIS; CORONAVIRUS; CORONAVIRUS INFECTION; COXSACKIE VIRUS B; DESICCATION; DISINFECTION; ENVIRONMENTAL TEMPERATURE; EPIDEMIC; HUMAN; HUMIDITY; INFECTION CONTROL; NONHUMAN; PARAINFLUENZA VIRUS 3; PH; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STANDARDIZATION; VIRAL CONTAMINATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS SURVIVAL; VIRUS TRANSMISSION; ZOONOSIS;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIVIRAL AGENTS; CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS;

CORONAVIRIDAE; CORONAVIRUS; RNA VIRUSES; SARS CORONAVIRUS;

EID: 84870600169     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4113044     Document Type: Review

References (134)

1. ICTV (International Committee on Taxonomy on Viruses). Virus Taxonomy: 2011 Release (current). Available online: http://ictvonline.org/virusTaxonomy.asp?version=2011 (Accessed on 24 September 2012).
2. Almeida, J.D.; Tyrrell, D.A. The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. J. Gen. Virol. 1967, 1, 175-178.
3. Bradburne, A.F.; Bynoe, M.L.; Tyrrell, D.A. Effects of a "new" human respiratory virus in volunteers. Br. Med. J. 1967, 3, 767-769.
4. Hamre, D.; Procknow, J.J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 1966, 121, 190-193.
5. McIntosh, K.; Dees, J.H.; Becker, W.B.; Kapikian, A.Z.; Chanock, R.M. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc. Natl. Acad. Sci. USA 1967, 57, 933-940.
6. Larson, H.E.; Reed, S.E.; Tyrrell, D.A. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J. Med. Virol. 1980, 5, 221-229.
7. Esper, F.; Weibel, C.; Ferguson, D.; Landry, M.L.; Kahn, J.S. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J. Infect. Dis. 2005, 191, 492-498.
8. Fouchier, R.A.; Hartwig, N.G.; Bestebroer, T.M.; Niemeyer, B.; de Jong, J.C.; Simon, J.H.; Osterhaus, A.D. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. USA 2004, 101, 6212-6216.
9. Van der Hoek, L.; Pyrc, K.; Jebbink, M.F.; Vermeulen-Oost, W.; Berkhout, R.J.; Wolthers, K.C.; Wertheim-van Dillen, P.M.; Kaandorp, J.; Spaargaren, J.; Berkhout, B. Identification of a new human coronavirus. Nat. Med. 2004, 10, 368-373.
10. Woo, P.C.; Lau, S.K.; Chu, C.M.; Chan, K.H.; Tsoi, H.W.; Huang, Y.; Wong, B.H.; Poon, R.W.; Cai, J.J.; Luk, W.K., et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 2005, 79, 884-895.
11. Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H.R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R.A., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1967-1976.
12. Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1953-1966.
13. Peiris, J.S.; Lai, S.T.; Poon, L.L.; Guan, Y.; Yam, L.Y.; Lim, W.; Nicholls, J.; Yee, W.K.; Yan, W.W.; Cheung, M.T., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319-1325.
14. WHO multicentre collaborative network for Severe Acute Respiratory Syndrome diagnosis. A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet 2003, 361, 1730-1733.
15. Arden, K.E.; Nissen, M.D.; Sloots, T.P.; Mackay, I.M. New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia. J. Med. Virol. 2005, 75, 455-462.
16. Bastien, N.; Anderson, K.; Hart, L.; Van Caeseele, P.; Brandt, K.; Milley, D.; Hatchette, T.; Weiss, E.C.; Li, Y. Human coronavirus NL63 infection in Canada. J. Infect. Dis. 2005, 191, 503-506.
17. Vabret, A.; Mourez, T.; Dina, J.; van der Hoek, L.; Gouarin, S.; Petitjean, J.; Brouard, J.; Freymuth, F. Human coronavirus NL63, France. Emerg. Infect. Dis. 2005, 11, 1225-1229.
18. Van der Hoek, L.; Sure, K.; Ihorst, G.; Stang, A.; Pyrc, K.; Jebbink, M.F.; Petersen, G.; Forster, J.; Berkhout, B.; Uberla, K. Croup is associated with the novel coronavirus NL63. PLoS Med. 2005, 2, e240.
19. Gerna, G.; Percivalle, E.; Sarasini, A.; Campanini, G.; Piralla, A.; Rovida, F.; Genini, E.; Marchi, A.; Baldanti, F. Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J. Clin. Virol. 2007, 38, 244-250.
20. Sloots, T.P.; McErlean, P.; Speicher, D.J.; Arden, K.E.; Nissen, M.D.; Mackay, I.M. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J. Clin. Virol. 2006, 35, 99-102.
21. Chiu, S.S.; Chan, K.H.; Chu, K.W.; Kwan, S.W.; Guan, Y.; Poon, L.L.; Peiris, J.S. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin. Infect. Dis. 2005, 40, 1721-1729.
22. Kon, M.; Watanabe, K.; Tazawa, T.; Tamura, T.; Tsukagoshi, H.; Noda, M.; Kimura, H.; Mizuta, K. Detection of human coronavirus NL63 and OC43 in children with acute respiratory infections in Niigata, Japan, between 2010 and 2011. Jpn. J. Infect. Dis. 2012, 65, 270-272.
23. Gerna, G.; Campanini, G.; Rovida, F.; Percivalle, E.; Sarasini, A.; Marchi, A.; Baldanti, F. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J. Med. Virol. 2006, 78, 938-949.
24. Esposito, S.; Bosis, S.; Niesters, H.G.; Tremolati, E.; Begliatti, E.; Rognoni, A.; Tagliabue, C.; Principi, N.; Osterhaus, A.D. Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. J. Med. Virol. 2006, 78, 1609-1615.
25. Vabret, A.; Dina, J.; Gouarin, S.; Petitjean, J.; Tripey, V.; Brouard, J.; Freymuth, F. Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France. J. Paediatr. Child. Health. 2008, 44, 176-181.
26. Talbot, H.K.; Shepherd, B.E.; Crowe, J.E., Jr.; Griffin, M.R.; Edwards, K.M.; Podsiad, A.B.; Tollefson, S.J.; Wright, P.F.; Williams, J.V. The pediatric burden of human coronaviruses evaluated for twenty years. Pediatr. Infect. Dis. J. 2009, 28, 682-687.
27. Vabret, A.; Mourez, T.; Gouarin, S.; Petitjean, J.; Freymuth, F. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin. Infect. Dis. 2003, 36, 985-989.
28. Van Elden, L.J.; van Loon, A.M.; van Alphen, F.; Hendriksen, K.A.; Hoepelman, A.I.; van Kraaij, M.G.; Oosterheert, J.J.; Schipper, P.; Schuurman, R.; Nijhuis, M. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J. Infect. Dis. 2004, 189, 652-657.
29. Riski, H.; Hovi, T. Coronavirus infections of man associated with diseases other than the common cold. J. Med. Virol. 1980, 6, 259-265.
30. Talbot, H.K.; Crowe, J.E., Jr.; Edwards, K.M.; Griffin, M.R.; Zhu, Y.; Weinberg, G.A.; Szilagyi, P.G.; Hall, C.B.; Podsiad, A.B.; Iwane, M., et al. Coronavirus infection and hospitalizations for acute respiratory illness in young children. J. Med. Virol. 2009, 81, 853-856.
31. Woo, P.C.; Lau, S.K.; Tsoi, H.W.; Huang, Y.; Poon, R.W.; Chu, C.M.; Lee, R.A.; Luk, W.K.; Wong, G.K.; Wong, B.H., et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J. Infect. Dis. 2005, 192, 1898-1907.
32. Gagneur, A.; Sizun, J.; Vallet, S.; Legr, M.C.; Picard, B.; Talbot, P.J. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J. Hosp. Infect. 2002, 51, 59-64.
33. Sizun, J.; Soupre, D.; Legrand, M.C.; Giroux, J.D.; Rubio, S.; Cauvin, J.M.; Chastel, C.; Alix, D.; de Parscau, L. Neonatal nosocomial respiratory infection with coronavirus: a prospective study in a neonatal intensive care unit. Acta Paediatr. 1995, 84, 617-620.
34. Falsey, A.R.; Walsh, E.E.; Hayden, F.G. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J. Infect. Dis. 2002, 185, 1338-1341.
35. Nicholson, K.G.; Kent, J.; Hammersley, V.; Cancio, E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997, 315, 1060-1064.
36. Pene, F.; Merlat, A.; Vabret, A.; Rozenberg, F.; Buzyn, A.; Dreyfus, F.; Cariou, A.; Freymuth, F.; Lebon, P. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infect. Dis. 2003, 37, 929-932.
37. Folz, R.J.; Elkordy, M.A. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. Chest 1999, 115, 901-905.
38. Chany, C.; Moscovici, O.; Lebon, P.; Rousset, S. Association of coronavirus infection with neonatal necrotizing enterocolitis. Pediatrics 1982, 69, 209-214.
39. Vabret, A.; Dina, J.; Gouarin, S.; Petitjean, J.; Corbet, S.; Freymuth, F. Detection of the new human coronavirus HKU1: a report of 6 cases. Clin. Infect. Dis. 2006, 42, 634-639.
40. Zhang, X.M.; Herbst, W.; Kousoulas, K.G.; Storz, J. Biological and genetic characterization of a hemagglutinating coronavirus isolated from a diarrhoeic child. J. Med. Virol. 1994, 44, 152-161.
41. Arbour, N.; Cote, G.; Lachance, C.; Tardieu, M.; Cashman, N.R.; Talbot, P.J. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J. Virol. 1999, 73, 3338-3350.
42. Arbour, N.; Ekande, S.; Cote, G.; Lachance, C.; Chagnon, F.; Tardieu, M.; Cashman, N.R.; Talbot, P.J. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. J. Virol. 1999, 73, 3326-3337.
43. Bonavia, A.; Arbour, N.; Yong, V.W.; Talbot, P.J. Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43. J. Virol. 1997, 71, 800-806.
44. Arbour, N.; Day, R.; Newcombe, J.; Talbot, P.J. Neuroinvasion by human respiratory coronaviruses. J. Virol. 2000, 74, 8913-8921.
45. Murray, R.S.; Brown, B.; Brian, D.; Cabirac, G.F. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann. Neurol. 1992, 31, 525-533.
46. Stewart, J.N.; Mounir, S.; Talbot, P.J. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 1992, 191, 502-505.
47. St-Jean, J.R.; Jacomy, H.; Desforges, M.; Vabret, A.; Freymuth, F.; Talbot, P.J. Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J. Virol. 2004, 78, 8824-8834.
48. Riski, H.; Hovi, T.; Frick, M.H. Carditis associated with coronavirus infection. Lancet 1980, 2, 100-101.
49. Hsu, L.Y.; Lee, C.C.; Green, J.A.; Ang, B.; Paton, N.I.; Lee, L.; Villacian, J.S.; Lim, P.L.; Earnest, A.; Leo, Y.S. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg. Infect. Dis. 2003, 9, 713-717.
50. Poutanen, S.M.; Low, D.E.; Henry, B.; Finkelstein, S.; Rose, D.; Green, K.; Tellier, R.; Draker, R.; Adachi, D.; Ayers, M., et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 2003, 348, 1995-2005.
51. WHO (World Health Organization). Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available online: http://www.who.int/csr/sars/country/table2004_04_21/en/index.html (Accessed on 21 February 2010).
52. Lee, N.; Hui, D.; Wu, A.; Chan, P.; Cameron, P.; Joynt, G.M.; Ahuja, A.; Yung, M.Y.; Leung, C.B.; To, K.F., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003, 348, 1986-1994.
53. Varia, M.; Wilson, S.; Sarwal, S.; McGeer, A.; Gournis, E.; Galanis, E.; Henry, B. Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. CMAJ 2003, 169, 285-292.
54. Zhao, Z.; Zhang, F.; Xu, M.; Huang, K.; Zhong, W.; Cai, W.; Yin, Z.; Huang, S.; Deng, Z.; Wei, M., et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J. Med. Microbiol. 2003, 52, 715-720.
55. Booth, C.M.; Matukas, L.M.; Tomlinson, G.A.; Rachlis, A.R.; Rose, D.B.; Dwosh, H.A.; Walmsley, S.L.; Mazzulli, T.; Avendano, M.; Derkach, P., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003, 289, 2801-2809.
56. Donnelly, C.A.; Ghani, A.C.; Leung, G.M.; Hedley, A.J.; Fraser, C.; Riley, S.; Abu-Raddad, L.J.; Ho, L.M.; Thach, T.Q.; Chau, P., et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003, 361, 1761-1766.
57. Peiris, J.S.; Chu, C.M.; Cheng, V.C.; Chan, K.S.; Hung, I.F.; Poon, L.L.; Law, K.I.; Tang, B.S.; Hon, T.Y.; Chan, C.S., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003, 361, 1767-1772.
58. Peiris, J.S.; Yuen, K.Y.; Osterhaus, A.D.; Stohr, K. The severe acute respiratory syndrome. N. Engl. J. Med. 2003, 349, 2431-2441.
59. WHO (World Health Organization). Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). Available online: http://www.who.int/csr/sars/en/WHOconsensus.pdf (Accessed on 25-09-12).
60. Hamming, I.; Timens, W.; Bulthuis, M.L.; Lely, A.T.; Navis, G.J.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004, 203, 631-637.
61. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450-454.
62. Dwosh, H.A.; Hong, H.H.; Austgarden, D.; Herman, S.; Schabas, R. Identification and containment of an outbreak of SARS in a community hospital. CMAJ 2003, 168, 1415-1420.
63. Ng, S.K. Possible role of an animal vector in the SARS outbreak at Amoy Gardens. Lancet 2003, 362, 570-572.
64. Vijgen, L.; Keyaerts, E.; Moes, E.; Thoelen, I.; Wollants, E.; Lemey, P.; Vandamme, A.M.; Van Ranst, M. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 2005, 79, 1595-1604.
65. Lau, S.K.; Woo, P.C.; Li, K.S.; Huang, Y.; Tsoi, H.W.; Wong, B.H.; Wong, S.S.; Leung, S.Y.; Chan, K.H.; Yuen, K.Y. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA 2005, 102, 14040-14045.
66. Li, W.; Shi, Z.; Yu, M.; Ren, W.; Smith, C.; Epstein, J.H.; Wang, H.; Crameri, G.; Hu, Z.; Zhang, H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310, 676-679.
67. Poon, L.L.; Chu, D.K.; Chan, K.H.; Wong, O.K.; Ellis, T.M.; Leung, Y.H.; Lau, S.K.; Woo, P.C.; Suen, K.Y.; Yuen, K.Y., et al. Identification of a novel coronavirus in bats. J. Virol. 2005, 79, 2001-2009.
68. Woo, P.C.; Lau, S.K.; Li, K.S.; Poon, R.W.; Wong, B.H.; Tsoi, H.W.; Yip, B.C.; Huang, Y.; Chan, K.H.; Yuen, K.Y. Molecular diversity of coronaviruses in bats. Virology 2006, 351, 180-187.
69. Kan, B.; Wang, M.; Jing, H.; Xu, H.; Jiang, X.; Yan, M.; Liang, W.; Zheng, H.; Wan, K.; Liu, Q., et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J. Virol. 2005, 79, 11892-11900.
70. Cinatl, J., Jr.; Michaelis, M.; Morgenstern, B.; Doerr, H.W. High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells. Int. J. Mol. Med. 2005, 15, 323-327.
71. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361, 2045-2046.
72. Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J., Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun. 2005, 326, 905-908.
73. Mazzulli, T.; Farcas, G.A.; Poutanen, S.M.; Willey, B.M.; Low, D.E.; Butany, J.; Asa, S.L.; Kain, K.C. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg. Infect. Dis. 2004, 10, 20-24.
74. Yamamoto, N.; Yang, R.; Yoshinaka, Y.; Amari, S.; Nakano, T.; Cinatl, J.; Rabenau, H.; Doerr, H.W.; Hunsmann, G.; Otaka, A., et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 2004, 318, 719-725.
75. Cinatl, J., Jr.; Michaelis, M.; Hoever, G.; Preiser, W.; Doerr, H.W. Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 2005, 66, 81-97.
76. Haagmans, B.L.; Osterhaus, A.D. Coronaviruses and their therapy. Antiviral Res. 2006, 71, 397-403.
77. Bisht, H.; Roberts, A.; Vogel, L.; Bukreyev, A.; Collins, P.L.; Murphy, B.R.; Subbarao, K.; Moss, B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA. 2004, 101, 6641-6646.
78. Kapadia, S.U.; Rose, J.K.; Lamirande, E.; Vogel, L.; Subbarao, K.; Roberts, A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340, 174-182.
79. Chen, Z.; Zhang, L.; Qin, C.; Ba, L.; Yi, C.E.; Zhang, F.; Wei, Q.; He, T.; Yu, W.; Yu, J., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 2005, 79, 2678-2688.
80. Bukreyev, A.; Lamirande, E.W.; Buchholz, U.J.; Vogel, L.N.; Elkins, W.R.; St Claire, M.; Murphy, B.R.; Subbarao, K.; Collins, P.L. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004, 363, 2122-2127.
81. Ishii, K.; Hasegawa, H.; Nagata, N.; Mizutani, T.; Morikawa, S.; Suzuki, T.; Taguchi, F.; Tashiro, M.; Takemori, T.; Miyamura, T., et al. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 2006, 351, 368-380.
82. See, R.H.; Zakhartchouk, A.N.; Petric, M.; Lawrence, D.J.; Mok, C.P.; Hogan, R.J.; Rowe, T.; Zitzow, L.A.; Karunakaran, K.P.; Hitt, M.M., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 2006, 87, 641-650.
83. Czub, M.; Weingartl, H.; Czub, S.; He, R.; Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005, 23, 2273-2279.
84. He, Y.; Li, J.; Heck, S.; Lustigman, S.; Jiang, S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 2006, 80, 5757-5767.
85. Zhou, Z.; Post, P.; Chubet, R.; Holtz, K.; McPherson, C.; Petric, M.; Cox, M. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006, 24, 3624-3631.
86. He, Y.; Zhou, Y.; Siddiqui, P.; Jiang, S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 2004, 325, 445-452.
87. Spruth, M.; Kistner, O.; Savidis-Dacho, H.; Hitter, E.; Crowe, B.; Gerencer, M.; Bruhl, P.; Grillberger, L.; Reiter, M.; Tauer, C., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006, 24, 652-661.
88. Tang, L.; Zhu, Q.; Qin, E.; Yu, M.; Ding, Z.; Shi, H.; Cheng, X.; Wang, C.; Chang, G.; Fang, F., et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 2004, 23, 391-394.
89. Xiong, S.; Wang, Y.F.; Zhang, M.Y.; Liu, X.J.; Zhang, C.H.; Liu, S.S.; Qian, C.W.; Li, J.X.; Lu, J.H.; Wan, Z.Y., et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol. Lett. 2004, 95, 139-143.
90. Takasuka, N.; Fujii, H.; Takahashi, Y.; Kasai, M.; Morikawa, S.; Itamura, S.; Ishii, K.; Sakaguchi, M.; Ohnishi, K.; Ohshima, M., et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunology 2004, 16, 1423-1430.
91. Stadler, K.; Roberts, A.; Becker, S.; Vogel, L.; Eickmann, M.; Kolesnikova, L.; Klenk, H.D.; Murphy, B.; Rappuoli, R.; Abrignani, S., et al. SARS vaccine protective in mice. Emerg. Infect. Dis. 2005, 11, 1312-1314.
92. Woo, P.C.; Lau, S.K.; Tsoi, H.W.; Chen, Z.W.; Wong, B.H.; Zhang, L.; Chan, J.K.; Wong, L.P.; He, W.; Ma, C., et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 2005, 23, 4959-4968.
93. Yang, Z.Y.; Kong, W.P.; Huang, Y.; Roberts, A.; Murphy, B.R.; Subbarao, K.; Nabel, G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428, 561-564.
94. Zhao, P.; Ke, J.S.; Qin, Z.L.; Ren, H.; Zhao, L.J.; Yu, J.G.; Gao, J.; Zhu, S.Y.; Qi, Z.T. DNA vaccine of SARS-Cov S gene induces antibody response in mice. Acta Biochim. Biophys. Sin. 2004, 36, 37-41.
95. Wang, Z.; Yuan, Z.; Matsumoto, M.; Hengge, U.R.; Chang, Y.F. Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice. Biochem. Biophys. Res. Commun. 2005, 327, 130-135.
96. Perlman, S.; Dandekar, A.A. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 2005, 5, 917-927.
97. Bolles, M.; Deming, D.; Long, K.; Agnihothram, S.; Whitmore, A.; Ferris, M.; Funkhouser, W.; Gralinski, L.; Totura, A.; Heise, M., et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011, 85, 12201-12215.
98. Deming, D.; Sheahan, T.; Heise, M.; Yount, B.; Davis, N.; Sims, A.; Suthar, M.; Harkema, J.; Whitmore, A.; Pickles, R., et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006, 3, e525.
99. Lokugamage, K.G.; Yoshikawa-Iwata, N.; Ito, N.; Watts, D.M.; Wyde, P.R.; Wang, N.; Newman, P.; Kent Tseng, C.T.; Peters, C.J.; Makino, S. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 2008, 26, 797-808.
100. Yasui, F.; Kai, C.; Kitabatake, M.; Inoue, S.; Yoneda, M.; Yokochi, S.; Kase, R.; Sekiguchi, S.; Morita, K.; Hishima, T., et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 2008, 181, 6337-6348.
101. Tseng, C.T.; Sbrana, E.; Iwata-Yoshikawa, N.; Newman, P.C.; Garron, T.; Atmar, R.L.; Peters, C.J.; Couch, R.B. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012, 7, e35421.
102. Olsen, S.J.; Chang, H.L.; Cheung, T.Y.; Tang, A.F.; Fisk, T.L.; Ooi, S.P.; Kuo, H.W.; Jiang, D.D.; Chen, K.T.; Lando, J., et al. Transmission of the severe acute respiratory syndrome on aircraft. N. Engl. J. Med. 2003, 349, 2416-2422.
103. Lee, S.H. The SARS epidemic in Hong Kong. J. Epidemiol. Community Health. 2003, 57, 652-654.
104. Ijaz, M.K.; Brunner, A.H.; Sattar, S.A.; Nair, R.C.; Johnson-Lussenburg, C.M. Survival characteristics of airborne human coronavirus 229E. J. Gen. Virol. 1985, 66 (Pt 12), 2743-2748.
105. Rabenau, H.F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H.W. Stability and inactivation of SARS coronavirus. Med. Microbiol. Immunol. 2005, 194, 1-6.
106. Duan, S.M.; Zhao, X.S.; Wen, R.F.; Huang, J.J.; Pi, G.H.; Zhang, S.X.; Han, J.; Bi, S.L.; Ruan, L.; Dong, X.P. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. Biomed. Environ. Sci. 2003, 16, 246-255.
107. Sizun, J.; Yu, M.W.; Talbot, P.J. Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections. J. Hosp. Infect. 2000, 46, 55-60.
108. Lai, M.Y.; Cheng, P.K.; Lim, W.W. Survival of severe acute respiratory syndrome coronavirus. Clin. Infect. Dis. 2005, 41, e67-71.
109. Chen, Y.C.; Huang, L.M.; Chan, C.C.; Su, C.P.; Chang, S.C.; Chang, Y.Y.; Chen, M.L.; Hung, C.C.; Chen, W.J.; Lin, F.Y., et al. SARS in hospital emergency room. Emerg. Infect. Dis. 2004, 10, 782-788.
110. Dowell, S.F.; Simmerman, J.M.; Erdman, D.D.; Wu, J.S.; Chaovavanich, A.; Javadi, M.; Yang, J.Y.; Anderson, L.J.; Tong, S.; Ho, M.S. Severe acute respiratory syndrome coronavirus on hospital surfaces. Clin. Infect. Dis. 2004, 39, 652-657.
111. Casanova, L.; Rutala, W.A.; Weber, D.J.; Sobsey, M.D. Survival of surrogate coronaviruses in water. Water Res. 2009, 43, 1893-1898.
112. Lamarre, A.; Talbot, P.J. Effect of pH and temperature on the infectivity of human coronavirus 229E. Can. J. Microbiol. 1989, 35, 972-974.
113. Sturman, L.S.; Ricard, C.S.; Holmes, K.V. Conformational change of the coronavirus peplomer glycoprotein at pH 8.0 and 37 degrees C correlates with virus aggregation and virus-induced cell fusion. J. Virol. 1990, 64, 3042-3050.
114. Daniel, C.; Talbot, P.J. Physico-chemical properties of murine hepatitis virus, strain A 59. Brief report. Arch. Virol. 1987, 96, 241-248.
115. Pocock, D.H.; Garwes, D.J. The influence of pH on the growth and stability of transmissible gastroenteritis virus in vitro. Arch. Virol. 1975, 49, 239-247.
116. Pratelli, A. Canine coronavirus inactivation with physical and chemical agents. Vet. J. 2008, 177, 71-79.
117. WHO (World Health Organization). First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. Available online: http://www.who.int/csr/sars/survival_2003_05_04/en/index.html (Accessed on 16 February 2010).
118. Lipsitch, M.; Cohen, T.; Cooper, B.; Robins, J.M.; Ma, S.; James, L.; Gopalakrishna, G.; Chew, S.K.; Tan, C.C.; Samore, M.H., et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 2003, 300, 1966-1970.
119. Riley, S.; Fraser, C.; Donnelly, C.A.; Ghani, A.C.; Abu-Raddad, L.J.; Hedley, A.J.; Leung, G.M.; Ho, L.M.; Lam, T.H.; Thach, T.Q., et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 2003, 300, 1961-1966.
120. Seto, W.H.; Tsang, D.; Yung, R.W.; Ching, T.Y.; Ng, T.K.; Ho, M.; Ho, L.M.; Peiris, J.S. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003, 361, 1519-1520.
121. WHO (World Health Organization). Global surveillance for Severe Acute Respiratory Syndrome (SARS). Wkly. Epidemiol. Rec. 2003, 78, 100-109.
122. AFNOR. Chemical disinfectants and-Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine-Test method and requirements (phase 2, step 1). NF EN 14476+A1. 2007
123. ASTM. Standard Test Method for Efficacy of Virucidal Agents Intended for Inanimate Environmental Surfaces. E1053-97 (last reapproval in 2002). 1997
124. ASTM. Standard Test Method for Efficacy of Antimicrobial Agents Against Viruses in Suspension. E1052-96 (last reapproval in 2002). 1996
125. ASTM. Standard Test Method for Neutralization of Virucidal Agents in Virucidal Efficacy Evaluations. E1482-04. 2004
126. ASTM (American Society for Testing and Materials). Standard Test Method for Determining the Virus-Eliminating Effectiveness of Liquid Hygienic Handwash and Handrub Agents Using the Fingerpads of Adult Volunteers. E1838-02. 2002
127. ASTM (American Society for Testing and Materials). Standard Test Method for Evaluation of Hygienic Handwash and Handrub Formulations for Virus-Eliminating Activity Using the Entire Hand. E2011-09. 2009
128. Sattar, S.A.; Springthorpe, V.S.; Karim, Y.; Loro, P. Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses. Epidemiol. Infect. 1989, 102, 493-505.
129. Kariwa, H.; Fujii, N.; Takashima, I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006, 212 Suppl 1, 119-123.
130. Geller, C.; Fontanay, S.; Finance, C.; Duval, R.E. A new Sephadex-based method for removing microbicidal and cytotoxic residues when testing antiseptics against viruses: Experiments with a human coronavirus as a model. J. Virol. Methods. 2009, 159, 217-226.
131. Geller, C.; Fontanay, S.; Mourer, M.; Dibama, H.M.; Regnouf-de-Vains, J.B.; Finance, C.; Duval, R.E. Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E. Antiviral Res. 2010, 88, 343-346.
132. Rabenau, H.F.; Kampf, G.; Cinatl, J.; Doerr, H.W. Efficacy of various disinfectants against SARS coronavirus. J. Hosp. Infect. 2005, 61, 107-111.
133. Hulkower, R.L.; Casanova, L.M.; Rutala, W.A.; Weber, D.J.; Sobsey, M.D. Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. Am. J. Infect. Control. 2011, 39, 401-407.
134. Dellanno, C.; Vega, Q.; Boesenberg, D. The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus. Am. J. Infect. Control. 2009, 37, 649-652.